医学。沙利度胺如何治疗癌症。
Medicine. How thalidomide works against cancer.
机构信息
Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.
出版信息
Science. 2014 Jan 17;343(6168):256-7. doi: 10.1126/science.1249543.
Abstract
The surprising ability of thalidomude and its analogs to treat various hematologic malignancies is through the loss of two transcription factors.
摘要
沙利度胺及其类似物通过两种转录因子的缺失来治疗各种血液系统恶性肿瘤的惊人能力。
相似文献
1
Medicine. How thalidomide works against cancer.医学。沙利度胺如何治疗癌症。
Science. 2014 Jan 17;343(6168):256-7. doi: 10.1126/science.1249543.
2
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.骨髓瘤药物来那度胺促进 cereblon 依赖性伊卡鲁素蛋白的降解。
Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29.
3
Haematological cancer: Ikaros--not a myth for myeloma.血液系统癌症：Ikaros——并非骨髓瘤的神话。
Nat Rev Clin Oncol. 2014 Feb;11(2):65. doi: 10.1038/nrclinonc.2013.237. Epub 2013 Dec 17.
4
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).免疫调节剂来那度胺和泊马度胺通过调节 E3 泛素连接酶复合物 CRL4(CRBN)，诱导 T 细胞抑制因子 Ikaros 和 Aiolos 的降解，从而共同刺激 T 细胞。
Br J Haematol. 2014 Mar;164(6):811-21. doi: 10.1111/bjh.12708. Epub 2013 Dec 13.
5
Multiple myeloma cells' capacity to decompose HO determines lenalidomide sensitivity.多发性骨髓瘤细胞分解HO的能力决定了来那度胺的敏感性。
Blood. 2017 Feb 23;129(8):991-1007. doi: 10.1182/blood-2016-09-738872. Epub 2016 Dec 27.
6
A peek into the atomic details of thalidomide's clinical effects.深入了解沙利度胺临床效应的原子细节。
Nat Struct Mol Biol. 2014 Sep;21(9):739-40. doi: 10.1038/nsmb.2882.
7
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.来那度胺导致多发性骨髓瘤细胞中 IKZF1 和 IKZF3 的选择性降解。
Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.
8
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.多发性骨髓瘤中cereblon结合蛋白的鉴定及其与免疫调节药物治疗反应和生存的关系。
Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.
9
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.通过 CRBN 定义噻唑并苯并二氮杂卓类似物靶向的人类 C2H2 锌指去泛素化酶。
Science. 2018 Nov 2;362(6414). doi: 10.1126/science.aat0572.
10
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.蛋白酶体抑制剂可阻断来那度胺在多发性骨髓瘤中诱导的Ikaro蛋白降解。
Haematologica. 2015 Aug;100(8):e315-7. doi: 10.3324/haematol.2015.124297. Epub 2015 May 14.
引用本文的文献
1
Therapeutic and Prognostic Relevance of Cancer Stem Cell Populations in Endometrial Cancer: A Narrative Review.子宫内膜癌中癌症干细胞群的治疗及预后相关性：一项叙述性综述
Diagnostics (Basel). 2025 Jul 25;15(15):1872. doi: 10.3390/diagnostics15151872.
2
The Importance of Cancer Stem Cells and Their Pathways in Endometrial Cancer: A Narrative Review.癌症干细胞及其信号通路在子宫内膜癌中的重要性：一篇综述
Cells. 2025 Apr 14;14(8):594. doi: 10.3390/cells14080594.
3
Rare biochemical & genetic conditions: clues for broader mechanistic insights.罕见的生化与遗传病症：获取更广泛机制性见解的线索
Cell Mol Life Sci. 2025 Apr 10;82(1):156. doi: 10.1007/s00018-025-05652-6.
4
Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies.基于来那度胺纳米混悬液的水凝胶局部透皮给药治疗黑色素瘤：体外和体内研究
Int J Pharm X. 2025 Jan 16;9:100316. doi: 10.1016/j.ijpx.2025.100316. eCollection 2025 Jun.
5
Drug Repurposing for Cancer Treatment: A Comprehensive Review.药物重用于癌症治疗：全面综述。
Int J Mol Sci. 2024 Nov 19;25(22):12441. doi: 10.3390/ijms252212441.
6
Alternative Cancer Therapeutics: Unpatentable Compounds and Their Potential in Oncology.替代癌症治疗方法：不可专利的化合物及其在肿瘤学中的潜力。
Pharmaceutics. 2024 Sep 23;16(9):1237. doi: 10.3390/pharmaceutics16091237.
7
Effects of Thalidomide on Erythropoiesis and Iron Homeostasis in Transfusion-Dependent β-Thalassemia.沙利度胺对依赖输血的β地中海贫血患者红细胞生成及铁稳态的影响
Mediterr J Hematol Infect Dis. 2024 Jan 1;16(1):e2024001. doi: 10.4084/MJHID.2024.001. eCollection 2024.
8
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?无免疫调节药物（IMiD）间期与IMiD用药顺序：哪种策略更适合来那度胺难治性骨髓瘤？
Life (Basel). 2023 Nov 20;13(11):2229. doi: 10.3390/life13112229.
9
Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma.来那度胺促进血栓形成，但不影响多发性骨髓瘤患者的血小板活化。
Int J Mol Sci. 2023 Sep 14;24(18):14097. doi: 10.3390/ijms241814097.
10
Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach.解读司美格鲁他扎相关抗血管生成作用的精确靶点：一种计算协同方法。
ACS Omega. 2023 Apr 20;8(17):14985-15002. doi: 10.1021/acsomega.2c07570. eCollection 2023 May 2.
本文引用的文献
1
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.来那度胺导致多发性骨髓瘤细胞中 IKZF1 和 IKZF3 的选择性降解。
Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29.
2
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.骨髓瘤药物来那度胺促进 cereblon 依赖性伊卡鲁素蛋白的降解。
Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29.
3
The clinical significance of cereblon expression in multiple myeloma.cereblon 在多发性骨髓瘤中的表达的临床意义。
Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.
4
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.免疫调节药物沙利度胺、来那度胺和泊马度胺在多发性骨髓瘤中的作用机制。
Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28.
5
IMWG consensus on maintenance therapy in multiple myeloma.IMWG 共识：多发性骨髓瘤的维持治疗。
Blood. 2012 Mar 29;119(13):3003-15. doi: 10.1182/blood-2011-11-374249. Epub 2012 Jan 23.
6
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Cereblon 表达是来那度胺和泊马度胺抗骨髓瘤活性所必需的。
Blood. 2011 Nov 3;118(18):4771-9. doi: 10.1182/blood-2011-05-356063. Epub 2011 Aug 22.
7
Identification of a primary target of thalidomide teratogenicity.确定沙利度胺致畸性的主要靶点。
Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319.
8
How I treat multiple myeloma in younger patients.我是如何治疗年轻患者的多发性骨髓瘤。
Blood. 2009 Dec 24;114(27):5436-43. doi: 10.1182/blood-2009-07-204651. Epub 2009 Oct 27.
9
IRF4 addiction in multiple myeloma.多发性骨髓瘤中的IRF4成瘾
Nature. 2008 Jul 10;454(7201):226-31. doi: 10.1038/nature07064. Epub 2008 Jun 22.
10
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.BCR-ABL1 淋巴细胞白血病的特征是 Ikaros 缺失。
Nature. 2008 May 1;453(7191):110-4. doi: 10.1038/nature06866. Epub 2008 Apr 13.
Zotero 插件